Compare WGO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | ABUS |
|---|---|---|
| Founded | 1958 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.1M | 929.6M |
| IPO Year | 1994 | 2008 |
| Metric | WGO | ABUS |
|---|---|---|
| Price | $31.81 | $4.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $42.78 | $5.00 |
| AVG Volume (30 Days) | 515.0K | ★ 1.9M |
| Earning Date | 03-25-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 106.82 | 55.26 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,985,674,000.00 | $14,083,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.69 | $239.71 |
| P/E Ratio | $88.39 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $28.40 | $3.04 |
| 52 Week High | $50.16 | $5.10 |
| Indicator | WGO | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 48.45 |
| Support Level | $28.81 | $4.17 |
| Resistance Level | $35.38 | $4.64 |
| Average True Range (ATR) | 1.07 | 0.17 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 38.95 | 50.81 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.